Ongoing Ebola virus disease outbreaks in the Democratic Republic of the Congo follow\nthe largest recorded outbreak in Western Africa (2013â??2016). To combat outbreaks, testing of\nmedical countermeasures (therapeutics or vaccines) requires a well-defined, reproducible, animal\nmodel. Here we present Ebola virus disease kinetics in 24 Chinese-origin rhesus monkeys exposed\nintramuscularly to a highly characterized, commercially available Kikwit Ebola virus Filovirus\nAnimal Non-Clinical Group (FANG) stock. Until reaching predetermined clinical disease endpoint\ncriteria, six animals underwent anesthesia for repeated clinical sampling and were compared to\nsix that did not. Groups of three animals were euthanized and necropsied on days 3, 4, 5, and 6\npost-exposure, respectively. In addition, three uninfected animals served as controls. Here, we present\ndetailed characterization of clinical and laboratory disease kinetics and complete blood counts, serum\nchemistries, Ebola virus titers, and disease kinetics for future medical countermeasure (MCM) study\ndesign and control data. We measured no statistical dierence in hematology, chemistry values, or\ntime to clinical endpoint in animals that were anesthetized for clinical sampling during the acute\ndisease compared to those that were not.
Loading....